Systemic sclerosis & Raynaud's
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis
Authors' conclusion
Using causal methods, our study is the first and largest suggesting that sildenafil might have benefits among SSc patients regarding diastolic dysfunction and altered ejection fraction occurrence.
Study context
- Population
- Patients with systemic sclerosis (SSc) in the French SSc national databaseavailable treatment data
- Participants
- 1,048 patients
- Exposure
- Vasodilator treatment vs no such treatment
- Outcome
- Diastolic dysfunction, altered ejection fraction <50% and PAH (average treatment effect)
Methodological detailsmulticentre, national database, longitudinal targeted minimum loss-based estimation, exploratory analysis
- Multicentre
- National database
- Longitudinal targeted minimum loss-based estimation
- Exploratory analysis
Main finding
As reported in the abstract
Average treatment effect of vasodilators on heart-related outcomes
Average treatment effect (ATE) on diastolic dysfunction at 3 years
−2.83%
95% CI −4.06 to −1.60P < 0.00001
Sildenafil
ATE on altered ejection fraction <50%
−0.88%
95% CI −1.70 to −0.05P = 0.037
Sildenafil
Observational data: associations, not effects.
Original publication
Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis. RMD Open. Published 9 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →